Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00740714 · ClinicalTrials.gov registry record · Phase 3
Effects of Coenzyme Q10 (CoQ) in Parkinson Disease
A Phase 3 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
NCT00740714 is a Phase 3 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 600 participants.
The verdict
NCT00740714, a Phase 3 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of high dosages of Coenzyme Q10 in slowing clinical decline in people who have early Parkinson disease.
Interventions
- DRUG Coenzyme Q10 with vitamin E
- DRUG placebo with vitamin E
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2008-12 |
| Est. Completion | 2011-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00740714
The ClinicalTrials.gov registry entry for NCT00740714 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Coenzyme Q10 with vitamin E is the first listed.
NCT00740714 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00740714 about?
NCT00740714 is a clinical study titled "Effects of Coenzyme Q10 (CoQ) in Parkinson Disease". The purpose of this study is to evaluate the safety and effectiveness of high dosages of Coenzyme Q10 in slowing clinical decline in people who have early Parkinson disease.
What is the current status of trial NCT00740714?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2008-12. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00740714?
The interventions under investigation include: Coenzyme Q10 with vitamin E (DRUG), placebo with vitamin E (DRUG).
Who is sponsoring clinical trial NCT00740714?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.